Kidney cancer

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
Moshe C. Ornstein, Laura S. Wood, Brian P. Hobbs, Kimberly D. Allman, Allison Martin, Michael Bevan, Timothy D. Gilligan, Jorge A. Garcia, Brian I. Rini

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 127; DOI: 10.1186/s40425-019-0615-z
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
Aung Naing, Jeffrey Infante, Sanjay Goel, Howard Burris, Chelsea Black, Shannon Marshall, Ikbel Achour, Susannah Barbee, Rena May, Chris Morehouse, Kristen Pollizzi, Xuyang Song, Keith Steele, Nairouz Elgeioushi, Farzana Walcott, Joyson Karakunnel, Patricia LoRusso, Amy Weise, Joseph Eder, Brendan Curti, Michael Oberst

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 225; DOI: 10.1186/s40425-019-0665-2
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Brian I. Rini, Dena Battle, Robert A. Figlin, Daniel J. George, Hans Hammers, Tom Hutson, Eric Jonasch, Richard W. Joseph, David F. McDermott, Robert J. Motzer, Sumanta K. Pal, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 354; DOI: 10.1186/s40425-019-0813-8
PD-L1 detection using ⁸⁹Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response
Joseph Vento, Aditi Mulgaonkar, Layton Woolford, Kien Nham, Alana Christie, Aditya Bagrodia, Alberto Diaz de Leon, Raquibul Hannan, Isaac Bowman, Renee M. McKay, Payal Kapur, Guiyang Hao, Xiankai Sun, James Brugarolas

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 144; DOI: 10.1186/s40425-019-0607-z
Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
David B. Page, Ariel Bulua Bourla, Anthony Daniyan, Jarushka Naidoo, Eric Smith, Melody Smith, Claire Friedman, Danny N. Khalil, Samuel Funt, Alexander N. Shoushtari, Willem W. Overwijk, Padmanee Sharma, Margaret K. Callahan

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (1) 25; DOI: 10.1186/s40425-015-0072-2
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
Ghayathri Jeyakumar, Seongho Kim, Naresh Bumma, Craig Landry, Cynthia Silski, Stacey Suisham, Brenda Dickow, Elisabeth Heath, Joseph Fontana, Ulka Vaishampayan

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 82; DOI: 10.1186/s40425-017-0287-5
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer
Raju R Raval, Andrew B Sharabi, Amanda J Walker, Charles G Drake, Padmanee Sharma

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 14; DOI: 10.1186/2051-1426-2-14
Gene expression in primary and metastatic kidney cancer to discover drivers of metastasis and targets for drug development
Amy Zhao, Arjun Guru, Sonpavde Guru, Eddy Yang, Yufeng Li

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P215; DOI: 10.1186/2051-1426-3-S2-P215
Phase I clinical trial of adoptive cellular immunotherapy with APN401 in patients with solid tumors
Pierre Triozzi, Mitra Kooshki, Angela Alistar, Rhonda Bitting, Amy Neal, Guenther Lametschwandtner, Hans Loibner

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P175; DOI: 10.1186/2051-1426-3-S2-P175
IFNγ-induced PD-L1 expression is JAK2 but not JAK1 dependent and its inhibition enhances NK-cetuximab mediated ADCC of HNSCC cells
Fernando Concha-Benavente, Robert L Ferris

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P199; DOI: 10.1186/2051-1426-2-S3-P199

Main menu

Kidney cancer

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Kidney cancer

Pages